ALXA – Alexza CEO Tom King, Interviewed by Ted Tenthoff

• Chapters
• 1. Alexza’s Eulogistic Symphony Deal, Partnering and Sales Strategies, and Cash ’till the Summer of 2010
• 2. Alexza’s Staccato: Vaporized Drugs in Multiple Indications, with a Safe and Effective Profile

1. Alexza’s Eulogistic Symphony Deal, Partnering and Sales Strategies, and Cash ’till the Summer of 2010

Ted Tenthoff asks Tom King of Alexza’s partnering strategy. Alexza will develop its own compounds for Psychiatry but will seek to partner in other areas, such as sleep – where Alexza is working with Endo Pharmaceuticals. Tom explains Alexza’s strong cash position, and the value of the Symphony transaction, which ultimately led to the development of 3 phase 3 products. Tom and Ted review other financing vehicles used by Alexza, and the production capabilities of the new Mountain View, CA GMP facility. Finally Ted asks Tom about Alexza’s discovery process, and method for prioritization of new drug development.

2. Alexza’s Staccato: Vaporized Drugs in Multiple Indications, with a Safe and Effective Profile

The Staccato system combines drug and device to provide a quick and convenient relief for patients with acute and intermittent conditions. Tom King (Alexza) and Ted Tenthoff (Piper Jaffray) explore the technology, mechanism of action, and safety profile. Tom and Ted to discuss the drugs in the pipeline and the indications, which include acute agitation associated with schizophrenia or bipolar disorders, breakthrough pain, panic attacks, and insomnia. They review the clinical data, and path for regulatory approval, in what Tom King calls a “crisp NDA plan” for early 2010. Tom and Ted also discuss the marketing opportunity and marketing challenges for these drugs and their innovative delivery system.

This interview was conducted at the NASDAQ Marketsite, on September 17th, 2008, in New York City.

Featuring:

• Thomas B. King, President and CEO, Alexza Pharmaceuticals
• Edward Tenthoff, Managing Director and Senior Biotech Research Analyst, Piper Jaffray

DISCLAIMER: VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

DISCLOSURES FOR THE UNIVERSE OF TED TENTHOFF

1. I or a household member have a financial interest in the securities of the following companies: none
2. I or a household member is an officer, director, or advisory board member of the following companies: none
3. I have received compensation within the past 12 months from the following companies : none
4. Piper Jaffray or its affiliates beneficially own 1% or more of any class of common equities of the following companies: none
5. The following companies have been investment banking clients of Piper Jaffray during the past 12 months: SGMO
6. Piper Jaffray expects to have the following companies as investment banking clients within the next three months: none
7. Other material conflicts of interest for Ted Tenthoff or Piper Jaffray regarding companies in my universe for which I am aware include: none
8. Piper Jaffray received non-investment banking securities-related compensation from the following companies during the past 12 months: none
9. Piper Jaffray makes a market in the securities of the following companies, and will buy and sell the securities of these companies on a principal basis: ACAD, ALNY, ALXA, ANDS, ARRY, CRXX, CYTX, DCGN, EXEL, HGSI, INFI, ISIS, LXRX, MYGN, OSIR, SGMO, ZGEN